--- title: "Centessa Pharmaceuticals | 10-Q: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/285257713.md" datetime: "2026-05-05T20:10:11.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285257713.md) - [en](https://longbridge.com/en/news/285257713.md) - [zh-HK](https://longbridge.com/zh-HK/news/285257713.md) --- # Centessa Pharmaceuticals | 10-Q: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -0.52, missing the estimate of USD -0.3963. EBIT: As of FY2026 Q1, the actual value is USD -82.18 M. Centessa Pharmaceuticals plc operates as a single segment, focusing on orexin-based neuroscience therapeutics and an early-stage immuno-oncology program . #### License and Other Revenue - For the three months ended March 31, 2026, License and Other Revenue was $0 million . - For the three months ended March 31, 2025, License and Other Revenue was $15,000 thousand, primarily from a non-refundable upfront payment related to the LockBody technology platform . #### Operating Expenses - **Research and Development (R&D) Expenses** increased to $59,891 thousand for the three months ended March 31, 2026, from $33,443 thousand in the prior year period, primarily due to higher development costs for the Orexin program and increased personnel expenses . - Cleminorexton program expenses rose by $6,800 thousand . - Other Orexin program expenses increased by $17,300 thousand . - LockBody technology program expenses decreased from $3,418 thousand in 2025 to $1,530 thousand in 2026 . - Discontinued R&D programs showed an income of -$52 thousand in 2026, compared to expenses of $2,917 thousand in 2025 . - Personnel expenses within R&D increased by $5,300 thousand . - Research tax incentives reduced R&D expenses by -$3,630 thousand in 2026, compared to -$4,259 thousand in 2025 . - **General and Administrative (G&A) Expenses** increased to $19,882 thousand for the three months ended March 31, 2026, from $12,334 thousand in the prior year period, driven by a $4,500 thousand rise in personnel costs and a $2,600 thousand increase in legal and professional fees . #### Loss from Operations - Loss from operations was -$79,773 thousand for the three months ended March 31, 2026, compared to -$30,777 thousand for the same period in 2025 . #### Net Loss - Net loss was -$79,241 thousand for the three months ended March 31, 2026, compared to -$26,135 thousand for the three months ended March 31, 2025 . #### Interest and Investment Income - Interest and investment income was $5,138 thousand for the three months ended March 31, 2026, a decrease of $2,500 thousand from $7,890 thousand in the prior year . #### Interest Expense - Interest expense was -$2,731 thousand for the three months ended March 31, 2026, a slight decrease of $200 thousand from -$2,877 thousand in the prior year . #### Other Non-Operating Income (Expense), Net - Other non-operating income (expense), net, was a loss of -$1,025 thousand for the three months ended March 31, 2026, compared to a gain of $1,026 thousand for the same period in 2025 . #### Cash Flow - **Net cash used in operating activities** was -$72,224 thousand for the three months ended March 31, 2026, compared to -$57,246 thousand for the same period in 2025 . - **Net cash provided by investing activities** was $42,707 thousand for the three months ended March 31, 2026, mainly from proceeds from redemption of fixed income investments . For the same period in 2025, net cash used in investing activities was -$222,388 thousand . - **Net cash provided by financing activities** was $30,467 thousand for the three months ended March 31, 2026, primarily from stock option exercises . For the same period in 2025, net cash provided by financing activities was $3,086 thousand . #### Liquidity and Capital Resources - As of March 31, 2026, Centessa Pharmaceuticals plc had cash, cash equivalents, and investments totaling $533.7 million . #### Future Outlook and Strategy Centessa Pharmaceuticals plc’s core business continues to focus on developing orexin-based neuroscience therapeutics and its LockBody technology platform . The company is in the process of being acquired by Eli Lilly and Company for $38.00 in cash per share plus contingent value rights, with the transaction anticipated to close in the third quarter of 2026 . Centessa Pharmaceuticals plc expects its current cash, cash equivalents, and investments of $533.7 million to fund operations into mid-2028, based on its existing operating model and development plans . ### Related Stocks - [CNTA.US](https://longbridge.com/en/quote/CNTA.US.md) ## Related News & Research - [Faron Pharmaceuticals LTD: Holding(s) In Company](https://longbridge.com/en/news/286725255.md) - [Electro-Sensors GAAP EPS of -$0.03, revenue of $2.6M](https://longbridge.com/en/news/286518577.md) - [PMV Pharmaceuticals (NASDAQ:PMVP) Will Have To Spend Its Cash Wisely](https://longbridge.com/en/news/286912396.md) - [Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA | HNSA Stock News](https://longbridge.com/en/news/286864132.md) - [Cosette Pharmaceuticals Appoints David Bell as Chief Commercial Officer (Brands)](https://longbridge.com/en/news/286911191.md)